OncoCyte Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

OncoCyte is forecast to grow earnings and revenue by 23.5% and 83.6% per annum respectively while EPS is expected to grow by 39.1% per annum.

Wichtige Informationen

23.5%

Wachstumsrate der Gewinne

39.1%

EPS-Wachstumsrate

Biotechs Gewinnwachstum27.1%
Wachstumsrate der Einnahmen83.6%
Zukünftige Eigenkapitalrenditen/a
Analystenabdeckung

Low

Zuletzt aktualisiert15 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oct 28
Is OncoCyte (NASDAQ:OCX) In A Good Position To Invest In Growth?

Oncocyte stock jumps ~15% after hours on contract for lung-cancer detection test

Aug 30

Revisiting OncoCyte Corp.

May 04

Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?

Jan 25
Is OncoCyte (NASDAQ:OCX) Using Debt Sensibly?

OncoCyte signs an at-the-market agreement to sell $50M of common stock

Jun 14

Despite Lacking Profits OncoCyte (NASDAQ:OCX) Seems To Be On Top Of Its Debt

Jun 02
Despite Lacking Profits OncoCyte (NASDAQ:OCX) Seems To Be On Top Of Its Debt

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:OCX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20267-20N/AN/A2
12/31/20252-23N/AN/A3
12/31/20241-25N/AN/A3
6/30/20241-37-18-18N/A
3/31/20241-40-19-19N/A
12/31/20232-26-24-23N/A
9/30/20231-22-28-27N/A
6/30/20231-17-38-36N/A
3/31/20231-11-43-41N/A
12/31/20221-19-50-46N/A
9/30/2022-1-22-47-43N/A
6/30/20220-34-46-43N/A
3/31/20221-43-42-39N/A
12/31/20212-44-38-36N/A
9/30/20215-35-37-35N/A
6/30/20214-28-32-30N/A
3/31/20212-26-31-29N/A
12/31/20201-30-27-26N/A
9/30/20201-32-27-25N/A
6/30/20200-30-25-24N/A
3/31/20200-26-21-20N/A
12/31/2019N/A-22-21-20N/A
9/30/2019N/A-19-17-17N/A
6/30/2019N/A-17-15-14N/A
3/31/2019N/A-16-16-16N/A
12/31/2018N/A-16-12-12N/A
9/30/2018N/A-15-13-13N/A
6/30/2018N/A-19-14-14N/A
3/31/2018N/A-18N/A-13N/A
12/31/2017N/A-19N/A-13N/A
9/30/2017N/A-19N/A-13N/A
6/30/2017N/A-14N/A-10N/A
3/31/2017N/A-13N/A-9N/A
12/31/2016N/A-11N/A-8N/A
9/30/2016N/A-12N/A-7N/A
6/30/2016N/A-11N/A-7N/A
3/31/2016N/A-10N/A-6N/A
12/31/2015N/A-9N/A-4N/A
9/30/2015N/A-7N/A-3N/A
6/30/2015N/A-5N/A-2N/A
3/31/2015N/A-5N/A-1N/A
12/31/2014N/A-5N/A-1N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: OCX is forecast to remain unprofitable over the next 3 years.

Ertrag vs. Markt: OCX is forecast to remain unprofitable over the next 3 years.

Hohe Wachstumserträge: OCX is forecast to remain unprofitable over the next 3 years.

Einnahmen vs. Markt: OCX's revenue (83.6% per year) is forecast to grow faster than the US market (8.9% per year).

Hohe Wachstumseinnahmen: OCX's revenue (83.6% per year) is forecast to grow faster than 20% per year.


Wachstumsprognosen für den Gewinn je Aktie


Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Insufficient data to determine if OCX's Return on Equity is forecast to be high in 3 years time


Wachstumsunternehmen entdecken